Port site resection after laparoscopy in advance ovarian cancer surgery: Time to abandon?

The use of laparoscopy in the treatment and management of advanced ovarian cancer is increasing among the gynaecologic oncologists. The development of port site metastases after laparoscopy is a concern and a matter of debate due to theoretical iatrogenic disease spread. Port site resection (PSR) ha...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Surgical oncology 2019-06, Vol.29, p.1-6
Hauptverfasser: Lago, Víctor, Gimenez, Laura, Matute, Luis, Padilla-Iserte, Pablo, Cárdenas-Rebollo, José Miguel, Gurrea, Marta, Montero, Beatriz, Montoliu, Guillermina, Domingo, Santiago
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The use of laparoscopy in the treatment and management of advanced ovarian cancer is increasing among the gynaecologic oncologists. The development of port site metastases after laparoscopy is a concern and a matter of debate due to theoretical iatrogenic disease spread. Port site resection (PSR) has been proposed as an option to avoid this scenario. One hundred and twenty-three patients with advanced ovarian cancer (FIGO III-IV) and with diagnostic laparoscopy were included and after cytoreductive surgery were classified into two groups: no port site resection (No-PSR) and port site resection (PSR). Based on the pathological results of all port site specimens, PSR was classified as positive port site metastasis (PSM+) and negative port site metastasis (PSM-). In 82 cases, the laparoscopic port site access was resected in the debulking surgery. At the final specimen examination, 49% presented as PSM+. No statistical differences regarding survival were found, either between the No-PSR and PSR groups (p = 0.28) or between the PSM+ and PSM - groups (p = 0.92). A higher wound complication rate was found in the PSR group (17% vs. 34%; p = 0.047). The RR (Relative Risk) of wound events for PSR was 2.42 (95% CI 1.09–5.35; p = 0.0296). To date, not only there is no data supporting PSR after laparoscopy in advanced ovarian cancer, but the role of PSM+ in prognosis also remains unclear. In patients in which laparoscopy is performed prior to the debulking procedure, the PSR may not be recommended in those cases of no macroscopic port site metastasis. •No statistical differences regarding survival were found between the No-PSR and PSR group.•No statistical differences regarding survival were found between the PSM+ and PSM-group.•A higher wound complication rate was found in the PSR group.•To date, not only there is no data supporting PSR after laparoscopy in advanced ovarian cancer.•The incidence of port site metastasis was high (49%) and its role in prognosis remains unclear.
ISSN:0960-7404
1879-3320
1879-3320
DOI:10.1016/j.suronc.2019.01.007